Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma

Cancer Letters

Volumn 362, Issue 2, 2015, Pages 192-198

  Zhao, Xuan ^a   Zhang, Zhen ^a   Li, Hong ^a   Huang, Jianmin ^a   Yang, Shuangning ^a   Xie, Tan ^a,b   Huang, Lan ^a   Yue, Dongli ^a   Xu, Li ^a   Wang, Liping ^a   Zhang, Weixing ^a   Zhang, Yi ^a,c,d  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU CHILDREN S HOSPITAL   (China)

^c ZHENGZHOU UNIVERSITY   (China)

^d Engineering Key Laboratory for Cell Therapy of Henan Province   (China)

Author keywords

Ag DC CIK; CIK; Disease free survival; Overall survival; Renal cell carcinoma

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IL4 PROTEIN, HUMAN; INTERLEUKIN 4; RECOMBINANT PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CD4 CD8 RATIO; CELL TRANSPLANTATION; CHILL; CONTROLLED STUDY; COUGHING; CYTOKINE INDUCED KILLER CELL; CYTOKINE PRODUCTION; DENDRITIC CELL; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYALGIA; NAUSEA AND VOMITING; NEPHRECTOMY; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY DISTRESS; RISK REDUCTION; SENSITIZATION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; ADOPTIVE IMMUNOTHERAPY; CARCINOMA, RENAL CELL; DRUG EFFECTS; IMMUNOLOGY; KIDNEY NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; SINGLE BLIND PROCEDURE;

ADULT; AGED; CARCINOMA, RENAL CELL; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INDIVIDUALIZED MEDICINE; INTERLEUKIN-4; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECOMBINANT PROTEINS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84928210715     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.03.043     Document Type: Article

References (44)

1. Pal S.K., Haas N.B. Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist 2014, 19:851-859.
2. Karumanchi S.A., Merchan J., Sukhatme V.P. Renal cancer: molecular mechanisms and newer therapeutic options. Curr. Opin. Nephrol. Hypertens 2002, 11:37-42.
3. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med 2007, 356:115-124.
4. Eggener S.E., Yossepowitch O., Pettus J.A., Snyder M.E., Motzer R.J., Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J. Clin. Oncol 2006, 24:3101-3106.
5. Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med 1998, 338:1272-1278.
6. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med 1991, 174:139-149.
7. Gutgemann S., Frank S., Strehl J., Schmidt-Wolf I.G. Cytokine-induced killer cells are type II natural killer T cells. Ger. Med. Sci 2007, 5. Doc07.
8. Gritzapis A.D., Dimitroulopoulos D., Paraskevas E., Baxevanis C.N., Papamichail M. Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol. Immunother 2002, 51:440-448.
9. Li R., Wang C., Liu L., Du C., Cao S., Yu J., et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol. Immunother 2012, 61:2125-2133.
10. Liu L., Zhang W., Qi X., Li H., Yu J., Wei S., et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin. Cancer Res 2012, 18:1751-1759.
11. Gao D., Li C., Xie X., Zhao P., Wei X., Sun W., et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS ONE 2014, 9. e93886.
12. Chung M.J., Park J.Y., Bang S., Park S.W., Song S.Y. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol. Immunother 2014, 63:939-946.
13. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol 2005, 5:296-306.
14. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
15. Palucka K., Banchereau J. Human dendritic cell subsets in vaccination. Curr. Opin. Immunol 2013, 25:396-402.
16. Thurnher M., Radmayr C., Ramoner R., Ebner S., Bock G., Klocker H., et al. Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer 1996, 68:1-7.
17. Marten A., Renoth S., von Lilienfeld-Toal M., Buttgereit P., Schakowski F., Glasmacher A., et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 2001, 86:1029-1037.
18. Wang Y.F., Kunda P.E., Lin J.W., Wang H., Chen X.M., Liu Q.L., et al. Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells. Oncol. Rep 2013, 29:1841-1850.
19. Gonzalez-Carmona M.A., Marten A., Hoffmann P., Schneider C., Sievers E., Schmidt-Wolf I.G., et al. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int 2006, 26:369-379.
20. Tan G., Zhang X., Feng H., Luo H., Wang Z. The therapeutic effect of cytokine-induced killer cells on pancreatic cancer enhanced by dendritic cells pulsed with K-ras mutant peptide. Clin. Dev. Immunol 2011, 2011. 649359.
21. Zhang Z., Zhao X., Zhang T., Wang L., Yang L., Huang L., et al. Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood. Cytotherapy 2015, 17:86-97.
22. Kim J.H., Lee Y., Bae Y.S., Kim W.S., Kim K., Im H.Y., et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin. Immunol 2007, 125:257-267.
23. Wang K., Gao X., Pang J., Liu X., Cai Y., Zhang Y., et al. Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells. Urol. Oncol 2009, 27:26-32.
24. Marten A., Ziske C., Schottker B., Renoth S., Weineck S., Buttgereit P., et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J. Immunother 2001, 24:502-510.
25. Price D.A., Brenchley J.M., Ruff L.E., Betts M.R., Hill B.J., Roederer M., et al. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J. Exp. Med 2005, 202:1349-1361.
26. Gros A., Robbins P.F., Yao X., Li Y.F., Turcotte S., Tran E., et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest 2014, 124:2246-2259.
27. Heinemann A., Zhao F., Pechlivanis S., Eberle J., Steinle A., Diederichs S., et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res 2012, 72:460-471.
28. Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 2004, 294:15-22.
29. Tang Y., Li X., Wang M., Zou Q., Zhao S., Sun B., et al. Increased numbers of NK cells, NKT-like cells, and NK inhibitory receptors in peripheral blood of patients with chronic obstructive pulmonary disease. Clin. Dev. Immunol 2013, 2013:721782.
30. Brusky J.P., Gailani F., Pathak A., Patel H., Aboseif S. High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis. BJU Int 2006, 97:279-280.
31. Turcotte S., Rosenberg S.A. Immunotherapy for metastatic solid cancers. Adv. Surg 2011, 45:341-360.
32. Rosenberg S.A., Mule J.J., Spiess P.J., Reichert C.M., Schwarz S.L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med 1985, 161:1169-1188.
33. Marincola F.M., White D.E., Wise A.P., Rosenberg S.A. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol 1995, 13:1110-1122.
34. Weng D.S., Zhou J., Zhou Q.M., Zhao M., Wang Q.J., Huang L.X., et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J. Immunother 2008, 31:63-71.
35. Pan K., Guan X.X., Li Y.Q., Zhao J.J., Li J.J., Qiu H.J., et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin. Cancer Res 2014, 20:3003-3011.
36. Wang D., Zhang B., Gao H., Ding G., Wu Q., Zhang J., et al. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer 2014, 14:251.
37. Li S.J., Zhang L.S., Chai Y., Zhang Y.F., Zhang Y.M., Zeng P.Y., et al. Killing activity of co-cultured cytokine-induced killer cells and dendritic cells against multi-drug resistant tumor cell lines. Zhonghua Zhong Liu Za Zhi 2007, 29:733-737.
38. Yang L., Ren B., Li H., Yu J., Cao S., Hao X., et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol. Immunother 2013, 62:65-73.
39. Shimizu K., Kuriyama H., Kjaergaard J., Lee W., Tanaka H., Shu S. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J. Immunother 2004, 27:265-272.
40. Yufeng D., Guocheng Z., Dongliang X., Rong F., Yuhong C., Ruying L., et al. Whole-tumor-antigen-pulsed dendritic cells elicit cytotoxic T-cell response against pediatric nasopharyngeal carcinoma in vitro. Med. Oncol 2009, 26:78-85.
41. Thorne S.H., Negrin R.S., Contag C.H. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006, 311:1780-1784.
42. Schmidt-Wolf I.G., Lefterova P., Mehta B.A., Fernandez L.P., Huhn D., Blume K.G., et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp. Hematol 1993, 21:1673-1679.
43. Robinson E., Segal R., Struminger L., Faraggi D., El'ad-Yarum R., Mekori T. Lymphocyte subpopulations in patients with multiple primary tumors. Cancer 1999, 85:2073-2076.
44. Kagi D., Ledermann B., Burki K., Seiler P., Odermatt B., Olsen K.J., et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994, 369:31-37.